ViewRay ( ) - 株価, ニュースと分析OTCPK:VRAY.Q

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

VRAY.Q 株式概要

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally.

会社概要

VRAY.Q ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	3/6
配当金	0/6

報酬

リスク分析

過去5年間で収益は年間6.6%減少しました。

意味のある時価総額がありません ( $18K )

過去3か月間の株価の変動は非常に激しい

キャッシュランウェイが1年未満である

ViewRay, Inc. 競合他社

Nanomix

OTCPK:NNMX

US$4.9k

American Bio Medica

OTCPK:ABMC

US$4.8k

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Motus GI Holdings

OTCPK:MOTS

US$279.0k

価格と性能

の歴代最高値、変動、値下がりまとめViewRay
過去の株価
現在の株価	US$0.0001
52週高値	US$4.96
52週安値	US$0.000001
ベータ	0.76
11ヶ月の変化	-98.88%
3ヶ月変化	-99.57%
1年変化	-100.00%
33年間の変化	-100.00%
5年間の変化	-100.00%
IPOからの変化	-100.00%

Recent updates

株主還元

	VRAY.Q	US Medical Equipment	US 市場
7D	0%	-0.6%	0.9%
1Y	-100.0%	20.8%	32.3%

業界別リターン: VRAY.Q過去 1 年間で1.7 % の収益を上げたUS Medical Equipment業界を下回りました。

リターン対市場: VRAY.Qは、過去 1 年間で21.8 % のリターンを上げたUS市場を下回りました。

価格変動

Is VRAY.Q's price volatile compared to industry and market?
VRAY.Q volatility
VRAY.Q Average Weekly Movement	2,748.1%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

安定した株価: VRAY.Qの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: VRAY.Qの週次ボラティリティは、過去 1 年間で1401%から2748%に増加しました。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2004	295	Paul Ziegler	www.viewray.com

ViewRay, Inc. 基礎のまとめ

ViewRay の収益と売上を時価総額と比較するとどうか。
VRAY.Q 基礎統計学
時価総額	US$18.34k
収益（TTM）	-US$110.41m
売上高(TTM)	US$105.86m

0.0x

P/Sレシオ

0.0x

PER（株価収益率

VRAY.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
VRAY.Q 損益計算書（TTM）
収益	US$105.86m
売上原価	US$97.34m
売上総利益	US$8.52m
その他の費用	US$118.94m
収益	-US$110.41m

直近の収益報告

Mar 31, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.60
グロス・マージン	8.05%
純利益率	-104.30%
有利子負債／自己資本比率	140.7%

VRAY.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

VRAY.Q 株式概要

報酬

リスク分析

ViewRay, Inc. 競合他社

OTCPK:NNMX

US$4.9k

OTCPK:ABMC

US$4.8k

OTCPK:LHDX.Q

US$4.2k

OTCPK:MOTS

US$279.0k

価格と性能

最新ニュース

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company